SCHEMBL6515113

SCHEMBL6515113

Cc1[nH]nc2c1c(=O)n(CCCNC(=O)c1ccc(C(F)(F)F)cc1)c1ccccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.48
KDR P35968 1/20 0.48
AURKB Q96GD4 1/20 0.48
CHEK1 O14757 3/20 0.44
PLK1 P53350 1/20 0.44
ALDH1A1 P00352 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
POLB P06746 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
NAMPT P43490 1/20 0.41
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HTT P42858 2/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6513140 0.92 AURKA (0.49) AURKAKDRAURKBCHEK1PLK1
SCHEMBL6517752 0.91 AURKA (0.50) AURKAKDRAURKBCHEK1PLK1
SCHEMBL6521705 0.90 AURKA (0.51) AURKAKDRAURKBCHEK1PLK1
SCHEMBL6514632 0.90 TRPV1 (0.47) AURKAKDRAURKBCHEK1PLK1
SCHEMBL6523103 0.89 CHEK1 (0.55) AURKAKDRAURKBCHEK1ALDH1A1
SCHEMBL6513075 0.88 AURKA (0.48) AURKAKDRAURKBCHEK1ALDH1A1
SCHEMBL6514908 0.87 AURKA (0.47) AURKAKDRAURKBCHEK1PLK1
SCHEMBL6515420 0.86 AURKA (0.47) AURKAKDRAURKBCHEK1ALDH1A1
SCHEMBL6519817 0.85 CHEK1 (0.50) AURKAKDRAURKBCHEK1PLK1
SCHEMBL6517509 0.84 AURKA (0.48) AURKAKDRAURKBCHEK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 AURKA 78/4885KDR 1094/4885AURKB 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.